FN2 Earnings Intelligence
BioMarin Pharmaceutical Inc. income statement
BioMarin Pharmaceutical Inc. (BMRN) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $587.3 | $724.5 | $755.1 | $942.8 | $1,311.7 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $1,846.3 | $2,096 | $2,419.2 | $2,853.9 | $3,221.3 |
| % Growth | -0.8% | 13.5% | 15.4% | 18.0% | 12.9% |
| Gross Profit | $1,375.8 | $1,612.4 | $1,904.4 | $2,273.7 | $2,503.8 |
| % Margin | 74.5% | 76.9% | 78.7% | 79.7% | 77.7% |
| EBITDA | $25.7 | $251.5 | $262.5 | $580.6 | $489 |
| % Margin | 1.4% | 12.0% | 10.8% | 20.3% | 15.2% |
| Net Income | -$64.1 | $141.6 | $167.6 | $426.9 | $348.9 |
| % Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| Diluted EPS | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| % Growth | -107.7% | 314.3% | 16.0% | 154.0% | -18.6% |
| Operating Cash Flow | $304.5 | $175.9 | $159.3 | $572.8 | $828 |
| CapEx | $95.6 | $121 | $96.7 | $85.4 | $103 |
| Free Cash Flow | $209 | $54.9 | $62.6 | $487.4 | $725 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | $1,846.3 | $2,096 | $2,419.2 | $2,853.9 | $3,221.3 |
| Gross Profit | $1,375.8 | $1,612.4 | $1,904.4 | $2,273.7 | $2,503.8 |
| EBITDA | $25.7 | $251.5 | $262.5 | $580.6 | $489 |
| Net Income | -$64.1 | $141.6 | $167.6 | $426.9 | $348.9 |
| Diluted EPS | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $587.3 | $724.5 | $755.1 | $942.8 | $1,311.7 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $304.5 | $175.9 | $159.3 | $572.8 | $828 |
| Capital Expenditure | $95.6 | $121 | $96.7 | $85.4 | $103 |
| Free Cash Flow | $209 | $54.9 | $62.6 | $487.4 | $725 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | -0.8% | 13.5% | 15.4% | 18.0% | 12.9% |
| Gross Margin | 74.5% | 76.9% | 78.7% | 79.7% | 77.7% |
| EBITDA Margin | 1.4% | 12.0% | 10.8% | 20.3% | 15.2% |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| FCF Margin | 11.3% | 2.6% | 2.6% | 17.1% | 22.5% |
| Diluted EPS Growth | -107.7% | 314.3% | 16.0% | 154.0% | -18.6% |
Get the BMRN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.